Onishi Kayono, Watanuki Rurina, Yokoe Takamichi, Iwatani Tsuguo, Yamauchi Chisako, Onishi Tatsuya
Department of Breast Surgery, 6-5-1Kashiwanoha, National Cancer Center Hospital East, Kashiwa, Japan.
Department of Translational Molecular Medicine, Saint John's Cancer Institute, Providence, Saint John's Health Center, Santa Monica, California, USA.
Case Rep Oncol. 2022 Aug 30;15(2):738-744. doi: 10.1159/000525295. eCollection 2022 May-Aug.
We present a case of two recurrences in the brachial lymph nodes after initial resection, which was performed for radical cure. A 66-year-old woman was diagnosed with left breast cancer T4bN3cM0 Stage IIIC and an immunohistochemistry assay showed estrogen receptor (ER) positivity (5%), progesterone-receptor (PgR) positivity (1%), human epidermal growth factor receptor-2 (HER2) positivity (3+), and low Ki-67 (15%). After four courses of adriamycin and cyclophosphamide, followed by four courses of trastuzumab plus docetaxel, the patient underwent left mastectomy and axillary dissection. Postoperatively, she was diagnosed with breast cancer ypT1cN0M0, and trastuzumab and anastrozole were started. Postoperative irradiation was performed. Three years and 5 months after the initial breast cancer surgery, she had left brachial lymph node recurrence. It was resected, and tamoxifen was administered postoperatively. One year and 9 months after, she had another left brachial lymph node recurrence, and it was resected. She received radiation therapy to her upper limb and started taking exemestane. After 1 year and 3 months since the second recurrence surgery, there has been no recurrence. Our case suggests that the replacement of regional lymph nodes with tumor cells may result in the reconstruction of lymph flow to the upper arm and the development of brachial lymph node metastasis. There are no reports of resection of the recurrent tumor in the brachial lymph node for curative treatment. Therefore, careful follow-up is important in the future.
我们报告一例在初次根治性切除术后肱部淋巴结出现两次复发的病例。一名66岁女性被诊断为左乳癌T4bN3cM0 III期,免疫组化检测显示雌激素受体(ER)阳性(5%)、孕激素受体(PgR)阳性(1%)、人表皮生长因子受体2(HER2)阳性(3+)以及低Ki-67(15%)。在接受四个疗程的阿霉素和环磷酰胺治疗,随后四个疗程的曲妥珠单抗加多西他赛后,患者接受了左乳切除术和腋窝淋巴结清扫术。术后,她被诊断为乳腺癌ypT1cN0M0,并开始使用曲妥珠单抗和阿那曲唑。进行了术后放疗。在初次乳腺癌手术后三年零五个月,她出现了左肱部淋巴结复发。进行了切除,术后给予他莫昔芬。一年零九个月后,她再次出现左肱部淋巴结复发,再次进行了切除。她接受了上肢放疗并开始服用依西美坦。自第二次复发手术一年零三个月以来,未再出现复发。我们的病例提示,肿瘤细胞替代区域淋巴结可能导致上肢淋巴引流重建以及肱部淋巴结转移的发生。目前尚无关于为根治性治疗而切除肱部淋巴结复发病灶的报道。因此,未来进行仔细的随访很重要。